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Abstract
Synthetic biology (SB) involves the alteration of living cells and biomolecules for specific purposes. Products developed using these
approaches could have significant societal benefits, but also pose uncertain risks to human and environmental health. Policymakers
currently face decisions regarding how stringently to regulate and monitor various SB applications. This is a complex task, in which
policymakers must balance uncertain economic, political, social, and health-related decision factors associated with SB use.We argue
that formal decision analytical tools could serve as a method to integrate available evidence-based information and expert judgment
on the impacts associated with SB innovations, synthesize that information into quantitative indicators, and serve as the first step
toward guiding governance of these emerging technologies. For this paper, we apply multi-criteria decision analysis to a specific case
of SB, a micro-robot based on biological cells called “cyberplasm.”We use data from a Delphi study to assess cyberplasm governance
options and demonstrate how such decision tools may be used for assessments of SB oversight.
Keywords: emerging technology, risk governance, synthetic biology, technology governance, uncertainty.
1. Introduction
Synthetic biology (SB) seeks to apply the principles of biological systems engineering through the design and assembly
of biologically inspired parts and systems that do not exist in nature in order to rewrite natural biological systems for
useful purposes. SB comes in many forms, from the genetic engineering of metabolic pathways into existing organisms
to the bottom-up construction of biological systems from macromolecule components to living systems based on
amino acids or genetic material that are synthesized (deLorenzo 2010). A key example of SB was demonstrated by
the J Craig Venter Institute in 2010 when they developed a synthetic genome for the bacteriumMycoplasma mycoides
and implanted it within a bacterial shell that had its own genome removed (Gibson et al. 2010; Hutchison et al. 2016).
Since then, visions of SB propose benefits to society across multiple sectors and improvement in a variety of processes,
ranging from environmental remediation to vaccine development to biofuel production, among others. However, SB is
also expected to be controversial for many reasons, including value-based objections of human interactions with nature
to concerns about potential human health, environmental, and socioeconomic risks (Kuzma & Tanji 2010; Church
et al. 2014).
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For example, one SB application currently under development, “cyberplasm” converges synthetic biology,
biomimicry, nanotechnology, and robotics to construct a micro-scale robot designed to be capable of sensing environ-
mental chemicals for remediating purposes (Voigt 2012). It has been proposed for use in detecting and treating path-
ogens within plants and animals in situ. Cyberplasm is a biohybrid that integrates engineered bacteria, yeast, and
mammalian cells to undertake device-like functions modeled after the sea lamprey. It is expected to be in full develop-
ment with a functional prototype by 2017.
As engineered microorganisms such as cyberplasm are envisioned to be biohybrids, it is likely that such technolo-
gies will “belong in a different risk category than toxic chemicals or radioactive materials” and will not fit risk assess-
ment approaches for living, genetically engineered, or other organisms where risks associated with gene flow and
invasiveness are of concern (Tucker & Zilinskas 2006, 31). Appropriate governance mechanisms have the potential
to diminish chances of serious harm andmaximize the likelihood that benefits of SB can be shared across a broad spec-
trum of society while respecting a diverse array of societal values. Schmidt et al. contend that SB requires “newmethods
of risk assessment to decide whether a new SB technique […] is safe enough (for human health, animals and the en-
vironment) for the use in restricted and/or less restricted environments” (2009, p.178). Such distinction from
established domains of risk characterization, assessment, and governance make any traditional risk assessment poten-
tially irrelevant to SB products because of the potentially unique risks and uncertainties posed by the use of self-
replicating microorganisms. While many effective governance structures for managing technological developments
are currently in place around the world, there may be a need to evolve and forecast governance actions because of
the revolutionary nature of SB technologies like cyberplasm. As SB requires potentially new and unique measures to
govern the risks associated with human and environmental health, policymakers for national governments are already
being forced to make decisions regarding how stringently to regulate, litigate, and monitor the various emerging tech-
nologies that are in development or coming to market (Mohan et al. 2012).
This is a complex task because of the inclusion of various stakeholders amidst a dearth of objective information.
Further complicating matters are the various factors that must be considered with any policy decision in this regard,
where policymakers are required to balance economic, political, social, and scientific risks and benefits associated with
the use of such technology. Such high-stakes decisions must often be undertaken in the absence of robust quantitative
data or extensive field research, making it more difficult for policymakers to identify optimal response options for
governing SB applications as they develop. To better understand these issues, some have suggested that researchers
make use of social scientific methods to demystify potential risk management strategies that could be employed given
the technology’s early stage development and use (Calvert & Martin 2009). Others have categorized SB products ac-
cording to sector and technologies involved (e.g. kinds of parts or methods) to identify risk categories of most concern
in order to develop scales of “precaution to promotion” that may be warranted (Kuzma & Tanji 2010).
Risk governance for emerging technologies has been given special attention in the literature because of the lack of
knowledge and experience with potential hazards, their interactions with systems in which they are embedded, and
their impacts. Emerging risks are characterized by uncertainty about potential consequences and probabilities of occur-
rence. The International Risk Governance Council (IRGC) has recommended that when risk problems involve high
uncertainty and ambiguity, processes limited to traditional agency and expert-driven risk analysis based on quantitative
data will not suffice (International Risk Governance Council [IRGC] 2006, 2015). If there is a high degree of uncer-
tainty, hazard criteria of reversibility, persistence, and ubiquity should be considered. Also, risk management should
include more cautionary approaches, such as close monitoring, small steps in introducing the hazard, strict contain-
ment, and systems that can absorb or tolerate surprises and that are resilient, flexible, and adaptive (IRGC 2006). In
situations of high ambiguity, there is no agreement among stakeholders and experts as to the questions of most impor-
tance for analyzing or mitigating risk, and there are conflicting values about what is to be protected or what risks should
be reduced. Under high ambiguity and uncertainty, broader societal discourse is most appropriate to frame problems
and management options with participation from a wide range of stakeholders and citizens (IRGC 2006).
In this paper, we propose a decision tool to aid policymakers, stakeholders, and societies with the task of
assessing governance options for various applications of SB innovation. While such applications of SB may or
may not come to commercial fruition, this decision aid affords regulators, policymakers, and stakeholders the op-
portunity to assess various tools of governance at their disposal for a variety of SB applications. This decision aid
may also help to make appropriate policy judgments based upon qualitative expert-derived information in lieu of
unavailable quantitative experimental data. This tool can be integrated into wider deliberative processes suggested
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by the IRGC to help stakeholders and experts develop scenarios and frame management options together (IRGC
2015). In this way, such a tool systematically quantifies and makes use of expert and stakeholder opinion that
may not always be reflected in the traditional regulatory policymaking process. We sought to identify answers to
the following research questions:
1 What governance options could be proposed regarding the potential applications of cyberplasm?
2 What is a good process for distilling expert derived data to recommend policy options for SB products, such as
with cyberplasm?
Answering both of these questions requires methodological approaches to: (i) acquire and interpret information
pertinent to the risks and benefits of cyberplasm, and (ii) analyze and rank decision alternatives based upon these risks
and benefits. To accomplish these aims, we make collective use of the Delphi methods to generate qualitative expert
interviews, as well as employing multi-criteria decision analysis (MCDA) to assess value judgments and rank gover-
nance alternatives for cyberplasm based upon expert input and discussion within scholarly literature (Linkov et al.
2013; Bates et al. 2016). Specifically, Question 1 is addressed through the use of the Delphi method, where individual
and collective opinion is assessed from subject experts to identify cyberplasm governance in the technology’s early stage
of development (Linstone & Turoff 2002; Berube et al. 2011). Question 2 is addressed through the use of MCDA, which
integrates qualitative findings from subject experts into a decision model that ranks governance options by their degree
of perceived optimality (Linkov et al. 2013; Bates et al. 2016).
When applications of emerging technologies, such as with SB, are generally lacking substantial objective data, the
use of subject expert opinions regarding the potential risks and benefits is required in order to inform policy decisions
related to how the technology should be regulated and governed. Transparent decision analytical tools such as MCDA
make this task possible in the immediate term. Using MCDA, expert opinion and judgment may be aggregated in a
formal and quantitative manner, ultimately affording its user the potential to make value judgments and trade-offs
based upon the perceived risks and benefits of the technology. Collectively, the use of the Delphi method (Linstone
& Turoff, 2002; Berube et al. 2011) andMCDA (Linkov et al. 2013; Bates et al. 2016) have been discussed as approaches
that can inform governance of emerging technologies within an environment of high uncertainty. Such an approach
may be helpful for regulators and other stakeholders seeking to drive the risk governance of synthetic biology products,
and this paper demonstrates how this process would work for the case of cyberplasm governance.
2. Case study
Modeled after the sea lamprey, cyberplasm is a biohybrid that integrates engineered mammalian cells and sensory neu-
rons to undertake device-like functions (Voigt 2012). The sea lamprey serves as the biological model for the
cyberplasm’s design. The animal swims by undulating its long tail in an uncomplicated wavelike motion and it also
has a relatively primitive nervous system. These characteristics are easy to mimic in terms of modeling. Biomimetic,
synthetic muscles are being designed to initiate the undulatory movement that will propel themicro-robot through wa-
ter, while sensors derived from yeast cells report environmental signals (Grubišić & Parpura 2015). Such signals allow
themicro-robot tomove toward their electronic stimulus to collect environmental data or delivermedical treatment on
site. Such a framework requires a strong integration of biological sensory neurons with the artificial electrical ones, in-
volving a level of interface scaffolding that facilitates the relay of signals throughout the nervous system. This is accom-
plished through the use of ultraviolet light on a silicon-derived organic polymer with a water coating. Through the
additional integration of carbon nanotubes, the scaffold is constructed to be electrically conductive and react to
predetermined stimuli (Szondy 2012).
Researchers have speculated that in the long-term, cyberplasm could eventually impact the healthcare industry
by improving biosensors and drug delivery systems through cellular machines after injection into the human body.
Cyberplasm is currently being researched and developed by an international team of scientists and engineers in the
United States (US) and the United Kingdom (UK), jointly funded by the National Science Foundation and the
Physical Sciences Research Council, respectively (Woodrow Wilson Center 2016). Oversight and risk analysis for
such an SB project is likely to be difficult given the convergent nature of the technologies used and the broad pos-
sibilities for deployment.
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3. Methods
This study employs MCDA to data acquired from a Policy Delphi study to assess cyberplasm governance (Linstone &
Turoff 2002). Methodologically, the use of the multi-round Delphi study allows for a consideration of individual and
collective discussion by identified subject experts on the subject of cyberplasm governance. This approach utilizes the
strengths of such a qualitative approach by acquiring a context-rich assessment of an SB product whose risks and ben-
efits would currently be impossible to quantitatively assess, while also mitigating the Delphi method’s traditional weak-
nesses by acquiring individual opinions and insight into the technology’s risks prior to group discussion (Linstone &
Turoff 2002). Likewise, MCDA serves as a method to utilize information derived from subject expert interviews and
rank decision alternatives via critical factors of consideration known as decision criteria (Bates et al. 2016). MCDA
may be of particular use to review governance options for emerging technologies like SB – the method offers some in-
sight via expert elicitation regarding value trade-offs and uncertainties that SB products may possess in their early stages
of development (Linkov et al. 2013; Bates et al. 2016; Subramanian et al. 2016).
The purposive sample of experts was chosen to provide “information rich” cases that can provide greater depth of
insight into the potential policy impacts and issues of cyberplasm governance. Individuals in various professional dis-
ciplines are deliberately included to gain multiple perspectives on the technology and its proper governance (Patton
2005). The list of potential panel members was compiled using a mixture of web database searches, literature reviews
for relevant author names, and prior knowledge and experience of the research team. The initial listing contained 234
experts originating from a variety of groups, including: attendance lists from research conferences and national and in-
ternational professional association meetings; editorial review boards for SB research journals; and government listed
panels of research, policy, and ethics review committees. Additional potential panel members were also added to the
list based on personal review from other SB researchers and analysts, as well as the research team.
The initial panel members represented a wide range of disciplines (n = 48) including chemistry, molecular biology,
and bio-engineering (n = 14, including those working on biological parts such as those used in cyberplasm who gave
firsthand accounts of risk and regulatory needs of the technology); policy, governance, and law (n = 14); ecology, en-
vironmental science, and toxicology (n = 6); and bioethics, philosophy, sociology, and science and technology studies
(STS) (n = 14). Thirty-five members completed the four rounds of the Delphi study (Table 1). Potential participation
contacts were limited because of the novelty of SB, as active research and development are limited to only a few dozen
well-known scholars and developers active in publication and conference presentations; such a respondent count is
consistent with similar research efforts on SB governance (Bates et al. 2016).
This Delphi study elicited expert judgments about the potential benefits and risks of cyberplasm, as well as judg-
ments regarding the ethical, legal, and societal issues of the technology. Named after the oracle of Delphi, the Delphi
method was designed to forecast decisionmaking under uncertain conditions when accurate information is unavailable
for ethical or financial reasons, or when subjective information is all that is available for a decision or policy assessment.
In a typical Delphi study, expert panel members respond to sets of open-ended and closed-ended questions individu-
ally, anonymously, and at their leisure, thus reducing group effect biases and allowing panel members to voice and
Table 1 Delphi rounds and participants
Round Method Description
One Standardized open-ended interview
protocol(n = 45)
Participants responded to a variety of questions about risk analysis, governance,
and societal issues for cyberplasm, as well as the other three cases (biomining, de-
extinction, and plant microbes for nitrogen-fixation). Interviews were
approximately 75 minutes in length.
Two Online quantitative survey (n = 34) Designed from preliminary round one findings. Included various scaled items
regarding risk governance issues associated with the case studies.
Three Face-to-face workshop and ordinal
ranking exercise (n = 35)
Focused on concept-mapping and mind-mapping exercises to generate lists of
challenges and opportunities for SB governance. Also included an ordinal
ranking exercise of ideal governance characteristics.
Four Online qualitative and quantitative
survey (n = 35)
Open-ended and closed-ended items and scales assessing factors that may
influence future policy and governance options concerning the case studies.
SB, synthetic biology.
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change their opinions without fear of repercussion. This method also encourages the equal flow of information be-
tween panel members and researchers and grants adequate time for experts to reflect on developing issues within
the study itself. This project used a modified version of the Delphi study, a Policy Delphi study, where the primary goal
is to “have an informed group present all the options and supporting evidence,” regarding the case of cyberplasm
(Linstone & Turoff 2002, p. 80). Given the uncertainties related to the risks and benefits posed by cyberplasm, a Policy
Delphi study was chosen in order to generate individual context-rich insight into the technology across the included
experts while also promoting group discussion and debate afterwards to discuss concerns or uncertainties related to
the technology’s characteristics and development (Berube et al. 2011; Linstone & Turoff 2002). Data presented forth-
with in this study were obtained from various phases throughout the Delphi study and the results are derived solely
from qualitative and quantitative data collected during the project.
Table 1 contains information regarding the project’s four-round elicitation process, including the number of re-
spondents at each stage, the type of elicitation conducted, and other general information.
4. Multi-criteria decision analysis model
To integrate and analyze responses fromDelphi participants, we utilizedMCDA, which is a method of decision analysis
that facilitates value trade-offs of complex and uncertain issues with various sources of information (Linkov &Moberg
2011). Specifically, MCDA integrates qualitative and quantitative information alike, allowing experts to voice their be-
liefs and opinions on a subject with limited field data or formal scientific agreement (Linkov & Moberg 2011; Linkov
et al. 2013). Further, MCDA tools can be used to review any disagreements or uncertainties signaled by subject experts
through the use of sensitivity analysis, making MCDA all the more helpful for regulators that have to address shifting
political, economic, social, and environmental factors as more information about specific products becomes available
(Saltelli et al. 1999; Linkov et al. 2013). Given these factors, MCDA serves as an appropriate method to analyze infor-
mation derived from the Delphi process and rank governance options for cyberplasm based upon relevant decision
criteria.
For this particular case, we make use of DECERNS decision analytic software, which allows for a multi-method
comparison of several decision analytical tools for a single dataset (Yatsalo et al. 2015). Other MCDAmodels have been
developed to assess the performance of oversight from a retrospective perspective, and have also been applied to case
studies, such as with genetically engineered organisms (Kuzma et al. 2008, 2009). This study also uses the case of tech-
nological product and multiple criteria for evaluation, but takes a prospective approach to help with future decisions
about emerging technologies.
Specifically, we utilizedmulti-attribute value theory (MAVT), in which expert perceptions of the technology’s char-
acteristics are converted to values and evaluated alongside subjective weights and information. This may be represented
mathematically as: V(a) = F(V1(a1),…,Vmam)). The overall objective of this methodology is to represent the
decisionmaker’s opinions and preferences in the value function v(a), where a symbolizes the vector of criteria to be
evaluated,wm the weighted values, and Vi(x) the partial value function for the criterion Ci (Yatsalo et al. 2007). MAVT
maintains underlying assumptions of stakeholder rationality and consistency in judgment, which we sought to assess
throughout the interview process (Belton 1986). We illustrate the process of our model’s creation in Figure 1, and fur-
ther explain how decision criteria and alternatives were constructed and scored.
The first step behind the construction of our value hierarchy consisted of identifying the various criteria by which a
decisionmaker would evaluate the risks and benefits of a cyberplasm product. This effort was driven primarily by as-
sessment of qualitative interview transcripts and responses from rounds 1 and 2. For additional argumentative valida-
tion behind a criteria’s construction, suggestions from SB risk governance literature were reviewed for consistency with
expert interview responses. This literature was constrained to articles that discussed the implications as well as the gov-
ernance of SB, including articles that discussed the prospective risks and benefits that SB products (particularly
cyberplasm)may offer to our decision criteria.With both sets of available information, the authors focused criteria con-
struction on those elements that were mentioned by more than one expert, and were present for discussion as relevant
in the consideration of risk and benefit by at least two articles published in peer-reviewed journals. This approach is
similar to the one used by Bates et al. (2016) and Linkov et al. (2012), who utilized literature and expert insight alike
to identify important factors for consideration that would influence MCDA output. Definitions for these criteria were
Regulatory action: Synthetic biology B. Trump et al.
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derived in a rank-maximizing fashion to make results found later in MAVT calculation more intuitive to readers re-
garding cyberplasm risk and benefit.
Using information generated from expert interviews and confirmed by emerging literature, the second step in-
cluded assessing the trade-offs and optimality of six alternative sets of policies that could be pursued by a given nation’s
regulatory bodies. Similar to criteria and sub-criteria formation in step one, alternatives construction was derived by
reviewing comments made in interview transcripts in interview rounds 1 and 2 alongside governance responses from
round 3. Similarly, additional justification was derived from scholarly literature regarding the possibility that such a gov-
ernance alternative could be deployed by a government agency for SB products in general. While these options are sim-
plified because of the emerging nature of the field, they do cover a wide breadth of potential regulatory options, and
could be easily modified in the future as SB applications for cyberplasm mature and commercialize. These options
are arranged in order of restriction placed upon an individual researcher or scientist in the field, including:
1 NoGovernance – no new or specific regulatory actions taken to govern or restrict SB research and development.
2 Internal review board (IRB) pre-research – research requires novel or technology-specific checkpoints, which are
monitored by within-organization review boards.
3 External review board (ERB) post-research – research requires debrief with external government agency after
completion or at certain checkpoints.
4 ERB pre-research – research proposals require approval and oversight from an external government review
board prior to research being conducted.
5 Secure labs – research is restricted to government-monitored laboratories only.
6 Moratorium – additional research and development is banned.Together, placeholders constructed for the deci-
sion criteria for cyberplasm governance and policy alternatives enabled us to build the model’s value hierarchy,
or the general structure showing relationships between decision criteria and policy alternatives. In Figure 2, we
detail the value hierarchy that breaks down the criteria and alternatives that must be considered in cyberplasm’s
multi-criteria decision framework.
After constructing the hierarchy, we reviewed interview transcripts and surveys with subject experts to acquire
weights for each criterion (in yellow), and scores for each subcriteria alternative linkage (in gray). Criteria weights were
derived from responses in interview rounds 2 and 4, while alternative scores were derived from survey responses and
transcript comments from rounds 2 and 3. Further, criteria weights were validated by question-specific ordinal scale
Figure 1 Flowchart ofmulti-criteria decision analysis (MCDA)model creation using scholarly literature, qualitative interviews, and
quantitative survey responses from four rounds of subject expert interviews.
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survey questions, allowing for an indication of the relative importance that a criterion should have based upon existing
knowledge of SB governance and decisionmaking. Likewise, alternative scores were derived by a mixture of question-
specific ordinal scale survey questions where available, or through indications of strength of statement made by respon-
dents alongside the relative confidence expressed by respondents through qualitative interview transcripts and re-
sponses in discussing a particular risk or benefit related to cyberplasm governance options. In cases where
respondents did not express confidence in their answers, or discussion for a particular policy alternative was limited,
further consideration of SB governance literature related to efforts to mitigate risk and promote benefit was included
in alternative scoring. This was minimized as much as possible, although general literature perusal was conducted
for all decision alternatives to promote consistency in the methodological approach for our model.
With regard to criteria weighting, survey questions asked specific queries about particular model criteria on a scale
of 1–10, where each response signifies the general level of importance that a particular criteria factors into an overall SB
policy decision. Individual criteria values were assessed as a simple arithmetic mean (see Eqn 1). Any blank responses
caused that particular respondent to be removed from average calculations for that given criteria. Later, all criteria




x′ ¼ a min xð Þ
Max xð Þ Min xð Þ (2)
Figure 2 Value hierarchy of cyberplasm governance and decisionmaking via product risk and benefit. ERB, IRB, Syn Bio
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Specific to alternative scoring, such quotes sought in transcript information included: “the environmental health
impacts are not at all important in this case,” which contributed to a score of 0 to most alternatives’ environmental
health score; or statements such as “I think that kind of less formal structures of governance that are less oriented
around regulations but more thinking about the shaping of technologies […] is actually something really important”
generally favored alternative scores with less restrictive governance overall. As a coding rule, each scoring item required
aminimumof two direct quotes to gauge the score, with separate coding passes taken and discrepancies reviewed by the
investigators. Quantitatively, alternative scores were assessed on a rank-maximized integer scale ranging from 0 to 3,
where each integer may be understood as: 0, no improvement;1, minor potential improvement; 2, significant potential
improvement; and 3, strong inevitable improvement.
Two reviewers were instructed to review specific key phrases within interview text and score alternatives accord-
ingly. Such key phrases centered on the degree of importance placed by the respondent upon the risk factors and reg-
ulatory needs of cyberplasm in a given context (i.e. economic or environmental). Further, the judges were told to base
their scores on at least four specific comments within interview text, and were to contrast these phrases with any dif-
fering opinions noted by other experts. The two score sheets were compared for consistency, and inconsistent scores
were reviewed by both judges to arrive at a consistent result. It is important to note that no inconsistency between
the two reviewers was greater than 1 integer, indicating that no significant gap in respondent perception arose.
5. Results
Model calculation involved the aggregation of score and criteria weights, and a subsequent summation of these prod-
ucts across all criteria (or weighted sum). The resultant final score serves as an evaluation of each policy alternative’s
optimality, with a higher score being more favorable. This standard model was evaluated alongside a model detailing
the level of confidence applied by each subject to their answer, or the level of surety that their answer was the correct
one. This comparison allowed for a review of whether “wild guesses” skewed the model significantly, or biased the re-
sults of a particular policy alternative.
For each of the six policy alternatives presented here, a net score was calculated, as shown in Figure 3. These calcu-
lations indicated small net performance optimality for the ERB pre-research alternative (score of 0.76). However, the
secure labs only (0.64), IRB pre-research (0.61), and ERB post-research (0.59) alternatives also performed well. We will
further discuss quantitative reasons why the alternatives score as they do, and perform sensitivity analysis to determine
which conditions the existing optimality may shift (Saltelli et al. 1999). Such an assessment allows for an understanding
of how resilient and dependable the selection of ERB pre-research is as the highest scoring governance option for SB
cyberplasm research and development (Saltelli et al. 1999; Stewart 2005).
To gain an additional understanding of the uncertainty and relative strength of expert knowledge, we review the
confidence scores (or the confidence expressed by subject experts related to the perceived risks and benefits that a
cyberplasm product poses for a given criteria) for the final raw results alongside the collective aggregation of the five
major criteria and their relative subcriteria. In Figure 4, the results of this analysis demonstrate general overall consis-
tency in the ranked list of results ( 2.5 percent or less in each of the six policy alternatives). This indicates that despite
some uncertainty in respondent answers, responses do not generally show any major outliers or points of concern that
could shift optimality in the final results. Unpacking this by reviewing the confidence-weighted scores for the individual
criteria weights is more distorted, particularly for the social criteria weight, which maintained an overall lower level of
confidence relative to the other criteria weights. Regardless, all but one individual data point falls below the 60 percent
level of confidence, or roughly a  5 percent difference from the overall confidence-weighted final score.
Lastly, we sought to further test the magnitude of the difference in scores by conducting sensitivity analysis on the
primary criteria’s weights (an example of the economic criteria is shown in Figure 5) (Saltelli et al. 1999; Linkov et al.
2012, 2013). Specifically, we reviewed the impact of increasing or reducing the degree of importance assigned to a given
criterion, with the difference removed or added to the other five criteria distributed equally.
Our sensitivity analysis indicates at least one crossover point in the weight distribution of each criteria, where the
different alternative may achieve a top score based upon a shift in criteria weights. However, not all of these crossover
points are reasonable, such as if social were given a weight approaching 0 (meaning that stakeholders place virtually no
value on social criteria to SB policy and decisionmaking) or if benefits were assigned a weight approaching 1 (meaning
that stakeholders only care about benefits as opposed to various concerns for other criteria). While optimality may shift
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or reach a point of ambivalence at the ends of the spectrum for these criteria, these scenarios are highly unlikely and are
generally unrealistic.
More realistically, the other three criteria (risks, political, economic) each contain possible crossover points that, if
weights on a given criterionmoved from one side of the breakeven point to another, themodel would call for a different
approach to cyberplasm governance. Specifically, the top scoring option switches from ERB pre-research to secure labs
and eventually even full moratorium once the criteria weight for risk reaches 64 percent (assuming all other criteria
Figure 4 Percentage differences between raw and confidence-weighted scores. ERB, IRB,
Figure 3 Cyberplasm governance alternatives: ranked list. ERB, IRB, MAVT,
Regulatory action: Synthetic biology B. Trump et al.
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weights are reduced proportionally). While this may seem distant from the current weight of 23.7 percent, it is within
the realm of possibility that, should a strong paradigm shift take place where government officials and stakeholders
place significantly more weight on avoiding the risk of emerging technologies, the optimal policy alternative to
cyberplasm development should be increasingly restricted commensurate with the government’s appetite for hazard.
The remaining two criteria (economic and political) also contain crossover points that generate a sensible narrative
based upon the driving factors that each criteria covers. For instance, the more a government decisionmaker cares for
the economic criteria driving cyberplasm development, the less stringent the optimal regulatory policy alternative
would become (from ERB pre-research to IRB pre-research to no new governance). Likewise, for the political criteria,
the more that decisionmakers value political factors behind emerging technology, the more likely they are to restrict
such technology development from taking place because of the potential negative outcomes that could accrue. While
these individual inflection points may or may not be interesting and realistic in their own right, they do represent po-
tential concern that, sometime in the future, changing priorities among government stakeholders and the public may
shift in such a way as to dramatically impact decisionmaking in this field. Although any shift in the optimal governance
alternative would require a substantial shift in priorities and risk/benefit trade-offs by regulatory decisionmakers, the
potential for such optimality to shift does warrant some discussion into the priorities that government stakeholders
want to exhibit in the governance process.
Figure 5 Sensitivity output: economic criteria weighting shift. ERB, IRB,
B. Trump et al. Regulatory action: Synthetic biology
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6. Discussion
The use of MCDA, Delphi studies, and other analytic tools are geared toward improving the identification of policy
options and decisionmaking under situations of high complexity and uncertainty, as in the investigated case of
cyberplasm. As the technology itself is further researched and developed, such decision analytic tools can help to focus
investigations on oversight and policy choices “upstream” from final technological development and use (Kuzma et al.
2008; Linkov et al. 2013). Decisions about how best to prepare for governing emerging technologies such as cyberplasm
have often made use of multiple lines of quantitative and qualitative information (such as modeling and monitoring,
risk analysis, cost–benefit analysis, and stakeholder preferences), which are typically combined in a subjective and un-
structured manner (Linkov et al. 2006). This ad hoc decision basis may ignore crucial factors for governance program
success and is likely to yield a suboptimal and regretted allocation of resources. Regulators, in partnership with stake-
holders, can significantly benefit from new modes of decision analysis like the one presented here that allow them to
acquire and analyze information about emerging technological applications in a manner that systematically incorpo-
rates qualitative and quantitative information regarding expert-derived risk and benefit data, along with defined gov-
ernance options. Tools such as the one described in this paper can also be integrated into stakeholder and public
participation exercises to develop scenarios and help frame management options under conditions of high uncertainty
and ambiguity (IRGC 2006, 2015).
Of the six policy options presented for the case of cyberplasm, the model calculated ERB pre-research is the most
optimal governance option. This form of governance is characterized by the need for approval from an external gov-
ernment review board prior to conducting research. It supports the IRGC recommendation for wider participatory ap-
proaches (i.e. ERB) under areas of high uncertainty and ambiguity that include confinement and the stepwise
introduction of emerging technologies into society (IRGC 2006). This conclusion was based on expert panel consider-
ations of the potential hazards associated with the development of the technology, as well as its potential applications.
This governance option demonstrated only slight net performance optimality compared with other governance op-
tions, including secured laboratory study, IRB pre-research, and ERB post-research, respectively. Notably, the recom-
mended governance option calculated by theMCDA system can be receptive to ranked weightings of its various criteria
(social, risks, political, and economic). However, inaccurate weighting of criteria may unjustly skew calculations. A
priori ranking of criteria importance must be considered carefully prior to calculation of recommended decision out-
puts and should reflect current environment and legislation schemes under which the technology being assessed will be
governed. Criteria ranking could also be performed in wider deliberative approaches to risk governance whereby stake-
holders, interested and affected parties, and experts convene to explore risk management options and scenarios (IRGC
2015). Only then can these tools be used appropriately to guide decisionmaking for cases such as cyberplasm that are
characterized by high complexity and uncertainty, in order to highlight oversight and policy choices “upstream” from
final technological development and use (Kuzma et al. 2008; Linkov et al. 2013).
Synthetic biology decisionmakers, stakeholders, and the public are likely to benefit from transparent, analytic ap-
proaches that identify and prioritize proactive governance options based on granular needs-assessments that incorpo-
rate expert-derived data and confidence estimates. As risk and benefit data analysis for emerging technologies continue
to improve, analytic schema like the one portrayed here for cyberplasm can be updated and evolved to incorporate new
criteria or extinguish irrelevant factors from the analysis. Furthermore, this investigation of policy options for the future
governance of cyberplasm is just one example of the benefit of MCDA as an option to inform initiatives of early-stage
governance of technologies while they are still in pre-production. SB technologies, nanotechnologies, and other revo-
lutionary technological applications are being developed at a frenetic pace. However, there is a dearth of proactive
rather than reactive initiatives being undertaken to evolve governance structures. Forecasting policy options of emerg-
ing technologies will likely require greater governance involvement in early-stages of development because of the rev-
olutionary nature of technologies like cyberplasm. Identifying and preparing for the use of hybrid and converging
technologies increases the uncertainty of the potential impacts, and even uses of such technologies. In such cases of ex-
treme uncertainty, the use of real data from expert studies like this one seems to be a most practical benchmark from
which we can forecast governance needs prior to technological diffusion.
Overall, while this paper uses cyberplasm as a “test case” for evaluating SB risks, benefits, and governance options, it
could easily be applied to a whole host of emerging technology applications that lack objective data yet have clear and
emerging governance needs to be met. There is no definitive guide to carrying out such research, but in general, using a
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transparent and robust interview and survey methodology while systematically selecting experts for inclusion would
offer helpful and much needed early stage policy and governance advice. This study also notes that governance deci-
sions are likely to be influenced by the prioritized needs of governing bodies and stakeholders. For instance, should
a governing body or stakeholders prioritize economic outcomes over others, the MCDA rubric and the DECERNS sys-
tem provide calibrated flexibility to assist with such needs and prescribe alternate policy options that can be calibrated
to reflect such preferences and/or adopt new information about the technology’s risk/benefit trade-offs related to
economics.
While we argue that this approach is a promising step forward in anticipatory governance and that tools like the one
demonstrated here are likely to remain among the best viable options for guiding early-stage governance of technolo-
gies, certain limitations should be noted. Specifically, using the Delphi method, highly influential group members can
have an effect during the face-to-face workshop (Franklin & Hart 2007). To limit such effects, the Delphi study used
here includedmultiple rounds of interviews, in which each respondent was interviewed before and after workshop par-
ticipation. Future work of this type may consider oversampling based on expected attrition, and may modify their use
of the Delphi method to better reflect their programmatic aims (Linstone & Turoff 2002).
7. Conclusion
While the decision analytic system described in this paper does not inherently advocate any particular policy options,
and where its outputs are likely to change as the field continues to develop and expand into commercialization, this sort
of investigation may serve as a heuristic to decisionmaking that prioritizes governance needs based on stakeholder and
expert elicitation. Ideally, future inputs of the tool would be revised and ranked based on wider deliberation of experts,
stakeholders, and policymakers, and outputs of the tool would be integrated into participatory processes to construct
different governance scenarios and risk management options.
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